JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $155
Quest Diagnostics Incorporated +6.85%
Quest Diagnostics Incorporated DGX | 157.47 | +6.85% |
JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:
DGX) with a Neutral and raises the price target from $152 to $155.